chlorthalidone (Hygroton)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Hygroton.

Indications

Dosage

Tabs: 25 mg.

Dosage adjustment in renal failure

Pharmacokinetics

  • bioavailability varies with different dosage forms
  • 90% bound mostly to erythrocytes
  • onset of action 2 hours
  • 1/2life 54 hours
  • duration of action: 24-72 hours
  • 30-60% of drug is excreted unchanged in the urine

elimination via kidney

1/2life = 56 hours

protein binding = 90 %

Adverse effects

Drug interactions

Mechanism of action

More general terms

Component of

References

  1. Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 123
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. 4.0 4.1 Dhalla IA et al Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults: A Population-Based Cohort Study. Ann Intern Med. 19 March 2013;158(6):447-455 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23552325 <Internet> http://annals.org/article.aspx?articleid=1667266
  5. 5.0 5.1 Deprecated Reference
  6. 6.0 6.1 Puttnam R, Davis BR, Pressel SL Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults. Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. Published online November 21, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27893045 <Internet> http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2587085
    Colon-Emeric CS, Lee R Cardiovascular Medications and Fractures. Dodging Complexity. JAMA Intern Med. Published online November 21, 2016. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27893011 <Internet> http://annals.org/aim/article/2588175/targeting-functional-decline-alzheimer-disease-randomized-trial
  7. 7.0 7.1 7.2 Hripcsak G, Suchard MA, Shea S et al Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med. Published online February 17, 2020. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32065600 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2760777
  8. 8.0 8.1 Agarwal R, Sinha AD, Cramer AE et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021 Nov 5; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34739197 https://www.nejm.org/doi/10.1056/NEJMoa2110730
  9. 9.0 9.1 Ishani A, Cushman WC, Leatherman SM et al Chlorthalidone vs. Hydrochlorothiazide for Hypertension - Cardiovascular Events. N Engl J Med 2022. Dec 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26760416 https://www.nejm.org/doi/10.1056/NEJMoa2212270

Database